Current advances in gene therapy of mitochondrial diseases

J Transl Med. 2022 Dec 5;20(1):562. doi: 10.1186/s12967-022-03685-0.

Abstract

Mitochondrial diseases (MD) are a heterogeneous group of multisystem disorders involving metabolic errors. MD are characterized by extremely heterogeneous symptoms, ranging from organ-specific to multisystem dysfunction with different clinical courses. Most primary MD are autosomal recessive but maternal inheritance (from mtDNA), autosomal dominant, and X-linked inheritance is also known. Mitochondria are unique energy-generating cellular organelles designed to survive and contain their own unique genetic coding material, a circular mtDNA fragment of approximately 16,000 base pairs. The mitochondrial genetic system incorporates closely interacting bi-genomic factors encoded by the nuclear and mitochondrial genomes. Understanding the dynamics of mitochondrial genetics supporting mitochondrial biogenesis is especially important for the development of strategies for the treatment of rare and difficult-to-diagnose diseases. Gene therapy is one of the methods for correcting mitochondrial disorders.

Keywords: Energy metabolism; Gene therapy; Heteroplasmy; Mitochondrial DNA; Mitochondrial diseases.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA, Mitochondrial / genetics
  • DNA, Mitochondrial / metabolism
  • Genetic Therapy
  • Humans
  • Inheritance Patterns
  • Mitochondria / genetics
  • Mitochondria / metabolism
  • Mitochondrial Diseases* / genetics
  • Mitochondrial Diseases* / therapy

Substances

  • DNA, Mitochondrial